Miller AB, Januzzi JL, O'Neill BJ, et al. - Given that a significant decrease in mortality as well as cardiovascular (CV)-related hospitalizations was achieved with tafamidis vs placebo in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) in an international, double-blind, placebo-controlled, randomized study named ATTR-ACT (Tafamidis in Transthyretin Cardiomyopathy Clinical Trial), researchers herein examined reasons for CV-associated death and hospitalization in ATTR-ACT to offer further insight into the progression of ATTR-CM as well as efficacy of tafamidis. Treatment with tafamidis vs placebo was associated with total CV-related deaths of 53 (20.1%) vs 50 (28.2%), respectively, and the most common causes were heart failure [HF] (15.5% tafamidis, 22.6% placebo), followed by sudden death (2.7% tafamidis, 5.1% placebo). With tafamidis vs placebo, less frequent were all predefined reasons of CV-associated death or hospitalization. These findings offer further understanding of CV disease progression in patients suffering from ATTR-CM, and the most common adjudicated reason for CV-associated hospitalization or death in ATTR-ACT was HF.